Halozyme Therapeutics Inc

詳細情報 Halozyme Therapeutics Inc 企業名

Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.

企業情報

企業コードHALO

会社名Halozyme Therapeutics Inc

上場日Jan 30, 2003

最高経営責任者「CEO」Dr. Helen I. Torley

従業員数350

証券種類Ordinary Share

決算期末Jan 30

本社所在地12390 El Camino Real

都市SAN DIEGO

証券取引所NASDAQ Global Select Consolidated

国United States of America

郵便番号92130

電話番号18587948889

ウェブサイトhttps://www.halozyme.com/

企業コードHALO

上場日Jan 30, 2003

最高経営責任者「CEO」Dr. Helen I. Torley

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Helen I. Torley

President, Chief Executive Officer, Director

733.72K

--

Mr. Matthew L. (Matt) Posard

Independent Director

74.04K

+5.96%

Ms. Nicole Labrosse

Chief Financial Officer, Senior Vice President

31.90K

--

Dr. Mahesh Krishnan, M.D.

Independent Director

--

Ms. Moni Miyashita

Independent Director

--

Mr. Jeffrey W. (Jeff) Henderson

Independent Chairman of the Board

--

Mr. Mark Snyder

Senior Vice President, Chief Compliance Officer, General Counsel, Secretary

--

Ms. Bernadette M. Connaughton

Independent Director

--

Ms. Barbara Duncan

Independent Director

--

Ms. Tram Bui

Vice President - Investor Relations and Corporate Communications

--

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Helen I. Torley

President, Chief Executive Officer, Director

733.72K

--

Mr. Matthew L. (Matt) Posard

Independent Director

74.04K

+5.96%

Ms. Nicole Labrosse

Chief Financial Officer, Senior Vice President

31.90K

--

Dr. Mahesh Krishnan, M.D.

Independent Director

--

Ms. Moni Miyashita

Independent Director

--

Mr. Jeffrey W. (Jeff) Henderson

Independent Chairman of the Board

--

収益内訳

通貨: USD更新時刻: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

事業別USD

会社名

収益

比率

Royalties

168.19M

63.50%

Sales of proprietary products

36.34M

13.72%

Sales of bulk rHuPH20

27.02M

10.20%

Sales-based milestones

15.00M

5.66%

Sales of device partnered products

14.68M

5.54%

Other

3.63M

1.37%

データなし

事業別

地域別

事業別USD

会社名

収益

比率

Royalties

168.19M

63.50%

Sales of proprietary products

36.34M

13.72%

Sales of bulk rHuPH20

27.02M

10.20%

Sales-based milestones

15.00M

5.66%

Sales of device partnered products

14.68M

5.54%

Other

3.63M

1.37%

株主

更新時刻: Tue, Jul 29

株主統計

種類

株主統計

比率

BlackRock Institutional Trust Company, N.A.

12.16%

The Vanguard Group, Inc.

10.39%

State Street Global Advisors (US)

4.91%

Snyder Capital Management, L.P.

2.98%

AllianceBernstein L.P.

2.61%

Other

66.94%

株主統計

比率

BlackRock Institutional Trust Company, N.A.

12.16%

The Vanguard Group, Inc.

10.39%

State Street Global Advisors (US)

4.91%

Snyder Capital Management, L.P.

2.98%

AllianceBernstein L.P.

2.61%

Other

66.94%

種類

株主統計

比率

Investment Advisor

58.36%

Investment Advisor/Hedge Fund

30.60%

Research Firm

4.57%

Pension Fund

2.37%

Hedge Fund

1.88%

Bank and Trust

1.48%

Sovereign Wealth Fund

1.16%

Individual Investor

1.11%

Insurance Company

0.12%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

1032

125.13M

101.55%

-10.49M

2025Q1

1043

127.91M

103.79%

-10.64M

2024Q4

999

127.73M

103.64%

-14.45M

2024Q3

953

129.39M

102.16%

-10.33M

2024Q2

905

126.24M

99.18%

-14.91M

2024Q1

870

127.71M

100.45%

-13.70M

2023Q4

850

128.82M

97.51%

-11.71M

2023Q3

836

127.73M

96.80%

-13.97M

2023Q2

838

128.24M

97.33%

-12.36M

2023Q1

833

129.53M

95.63%

-10.61M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

BlackRock Institutional Trust Company, N.A.

14.99M

12.16%

-268.69K

-1.76%

Mar 31, 2025

The Vanguard Group, Inc.

12.80M

10.39%

-451.45K

-3.41%

Mar 31, 2025

State Street Global Advisors (US)

6.05M

4.91%

-1.13M

-15.75%

Mar 31, 2025

Snyder Capital Management, L.P.

3.67M

2.98%

-494.15K

-11.85%

Mar 31, 2025

AllianceBernstein L.P.

3.22M

2.61%

+146.68K

+4.78%

Mar 31, 2025

Geode Capital Management, L.L.C.

3.17M

2.57%

+105.17K

+3.43%

Mar 31, 2025

Macquarie Investment Management

2.67M

2.17%

-231.21K

-7.96%

Mar 31, 2025

Invesco Capital Management LLC

2.42M

1.96%

+628.59K

+35.15%

Mar 31, 2025

Dimensional Fund Advisors, L.P.

2.03M

1.65%

+95.60K

+4.94%

Mar 31, 2025

Congress Asset Management Company, LLP

2.13M

1.73%

+172.97K

+8.83%

Mar 31, 2025

詳細を見る

59.740USD

Halozyme Therapeutics Inc

59.740

概要

企業名

金融